Sign in

CIK 0001635088

  • Large accelerated filer

Roivant Sciences Ltd.

Sign in to watch
Ticker
ROIV
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Mar 31
Incorporated
Bermuda
Entity type
Operating
EIN
981173944
Phone
+44 12955950
Business address
7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$70,369,463
in 12 filings, $45.5M under 10b5-1 plans

Net −$70,369,463. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2024-02-09 Venker Eric President & COO Option exercise · Stock Option (Right to Buy) 10b5-1 −96,950 12,526,234
2024-01-28 Pulik Richard CFO Shares withheld for taxes 10b5-1 −1,896 $10.37 $20K 271,183
2024-01-20 Gline Matthew CEO Shares withheld for taxes 10b5-1 −10,945 $10.35 $113K 1,011,953
2024-01-20 Kumar Rakhi Chief Accounting Officer Shares withheld for taxes 10b5-1 −1,506 $10.35 $16K 190,783
2024-01-20 Venker Eric President & COO Shares withheld for taxes 10b5-1 −12,377 $10.35 $128K 532,207
2024-01-19 MOMTAZEE JAMES C Director Grant or award +1,570 76,339
2024-01-19 Fitzgerald Meghan Director Grant or award +1,328 12,686
2024-01-19 Epperly Melissa B, Director Grant or award +1,207 21,538
2024-01-19 Oren Ilan Director Grant or award +3,366 78,342
2024-01-02 Ramaswamy Vivek 10% owner Sale −3,000,000 $11.05 $33.1M 51,929,426
2023-12-28 Pulik Richard CFO Shares withheld for taxes 10b5-1 −1,913 $11.37 $22K 273,079
2023-12-27 Ramaswamy Vivek 10% owner Option exercise 10b5-1 +275,227 55,063,337
2023-12-27 Ramaswamy Vivek 10% owner Shares withheld for taxes 10b5-1 −133,911 $11.58 $1.6M 54,929,426
2023-12-27 Ramaswamy Vivek 10% owner Option exercise · Capped Value Appreciation Rights 10b5-1 −611,393 $6.40 $3.9M 7,132,921
2023-12-27 Ramaswamy Vivek 10% owner Option exercise · Capped Value Appreciation Rights 10b5-1 −251,538 $11.50 $2.9M 11,570,769
2023-12-27 Gline Matthew CEO Option exercise 10b5-1 +38,453 1,044,941
2023-12-27 Gline Matthew CEO Shares withheld for taxes 10b5-1 −22,043 $11.58 $255K 1,022,898
2023-12-27 Gline Matthew CEO Option exercise · Capped Value Appreciation Rights 10b5-1 −85,232 $6.40 $545K 994,373
2023-12-27 Gline Matthew CEO Option exercise · Capped Value Appreciation Rights 10b5-1 −47,351 $11.50 $545K 2,178,150
2023-12-27 Sukhatme Mayukh Pres&Chief Investment Officer Option exercise +71,365 3,289,115

Page 34 of 38 · 748 trades